MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) CEO Roby Zomer joined Proactive to discuss its new capital raise of £5.5mln via a share placing – cash that will be used to fund emergency use authorisation applications for the use of its lead asset in COVID.
Zomer says it said it plans to begin the approval process for CimetrA in India before rolling it out to a total of five countries in central and eastern Europe and central Asia. CimetrA is a pharmaceutical synthetic composition of Curcumin and Boswellia that is thought to have an anti-inflammatory effect as well as potentially modulating the immune system.